Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY: Depemokimab in Adults with Hypereosinophilic Syndrome
jRCT2051220052Recruiting
- Sponsor
- GSK
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Depemokimab arm with Placebo arm (2 arms). Primary endpoint: Frequency of HES flares during the 52-week study intervention period. Started Oct 2022; status: recruiting.
02
Drugs
depemokimab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on jRCT2051220052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220052.